ETS2 Polyclonal antibody
ETS2 Polyclonal Antibody for IP, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse
Applications
WB, IP, ELISA
Conjugate
Unconjugated
Cat no : 12280-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | K-562 cells, HeLa cells, MCF-7 cells, mouse kidney tissue, PC-3 cells |
Positive IP detected in | HeLa cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB |
Sample-dependent, check data in validation data gallery |
Published Applications
WB | See 2 publications below |
Product Information
12280-1-AP targets ETS2 in WB, IP, ELISA applications and shows reactivity with human, mouse samples.
Tested Reactivity | human, mouse |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | ETS2 fusion protein Ag2929 |
Full Name | v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) |
Calculated molecular weight | 469 aa, 53 kDa |
Observed molecular weight | 53 kDa |
GenBank accession number | BC017040 |
Gene symbol | ETS2 |
Gene ID (NCBI) | 2114 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
WB protocol for ETS2 antibody 12280-1-AP | Download protocol |
IP protocol for ETS2 antibody 12280-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Cell Death Dis The overexpression of Tipe2 in CRC cells suppresses survival while endogenous Tipe2 accelerates AOM/DSS induced-tumor initiation. | ||
Cell Death Dis A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer |